BioDiagnostics is seeking global distributors for its CDC recommended HSV-2 BioCard™
The BioCard™ HSV-2 testing technology was initially manufactured by BioDiagnostics as a low-cost screening method to detect undiagnosed infections of Genital Herpes Simplex Virus Type 2 (HSV-2). It later became recommended by the CDC for confirmation of (HSV-2) referred to in the “Sexually Transmitted Infections Treatment Guidelines, 2021” (referred to in its BioKit™ private label).
The development of the BioCard™ technology brought together the speed of rapid tests with an accuracy on a par or better than ELISA or CLIA systems. This enabled unrestricted sample throughput without analysers and their high associated costs, providing access to smaller clinics as well as large laboratory groups all utilising the BioCard™ technology.
Visit Herpes Simplex Virus Rapid Test – HSV2 BioCard™ Rapid Test from BioDiagnostics for more details, and to explore becoming distributor for this essential test in your territory.